EMBC - embecta Tidepool team up to develop automated insulin delivery system

2023-05-12 06:33:26 ET

• Embecta ( NASDAQ: EMBC ) is collaborating with Tidepool to develop an automated insulin delivery (AID) system for people with type 2 diabetes (T2D).
• Embecta said it will use the nonprofit organization Tidepool's expertise in diabetes management software to develop the AID algorithm for its closed-loop patch pump system designed for people with T2D, for which it received FDA breakthrough device designation.
• "The recent 510(k) clearance of Tidepool Loop — a fully interoperable automated insulin dosing app which started as a patient-led initiative — affirms that Tidepool’s approach to AID system development combines patient insights with a robust diabetes management solution," said embecta's Chief Medical Officer Henry Anhalt.

For further details see: